OncoPed Select

Child-Sized. Targeted. Actionable.

Cancer, one of the leading causes of death among children, has a new enemy. PierianDx has combined forces with leading children’s hospitals to offer a “right sized” Next Generation Sequencing (NGS) test uniquely designed for children called OncoPed Select. There are two OncoPed Select assays: The OncoPed Select assay Includes total exonic coverage for somatic variants in 71 genes and reporting of fusion transcripts from 51 genes; the OncoPed Select Research assay Includes total exonic coverage for somatic variants in 361 genes and reporting of fusion transcripts from 308 genes.

 CONTACT US

About the OncoPed
Select Assay

More than one year ago, leaders from PierianDx and leading children’s hospitals discussed how to fill a glaring gap in pediatric oncology; there was no clinically-focused pediatric somatic cancer assay on the market. Additionally, many children’s hospitals across the country didn’t have the volume needed to warrant the validation of such specific genomic testing for children.

The result of this feedback was the creation of OncoPed Select, malignancy and research panels specifically tailored to address childhood cancers. The OncoPed assays are the right balance between assay breadth, depth and price.

Contact us today about the OncoPed Select Assay – the right fit for the right cause.

 CONTACT US

OncoPed Select Features

  • Validated by leading children’s hospitals and PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting

  • Created to achieve the right balance between gene breadth, depth and affordability

  • Between 14 and 21 days turnaround time (TAT)

  • Unlike the traditional “send out” model, the partner has the option to retain all data, brand the test as their own, and review and sign out cases

Frequently Asked Questions

What types of variants are covered?

Variant Types: Single nucleotide variants (SNVs), Small insertions and deletions (indels), Copy number variants (CNVs), Structural variants (SVs), such as translocations

What are the indications for which this test is appropriate?

Complete the provided requisition form and PierianDx will coordinate material collection with the pathology laboratory.

What are the indications for which this test is appropriate?

Complete the provided requisition form and PierianDx will coordinate material collection with the pathology laboratory.

What’s the cost?

Assay is available by institutional billing for $3,000 (OncoPed Select) and $4,000 (OncoPed Select Research) respectively. At this time, PierianDx does not provide assistance for insurance pre-authorization or billing.

Who will perform the sign-out?

Qualified medical directors employed by PierianDx certified by American Board of Pathology in anatomic and clinical pathology, with subspecialty in molecular genetic pathology.  Our primary reviewer for OncoPed is a laboratory director from ARUM whose research interests include genomic diagnostics in solid tumors and molecular diagnostic methods in pediatric oncology.

What sample formats are accepted?

For solid tumors, the following specimen types are acceptable:

  1. Formalin fixed, paraffin embedded (FFPE) block(s) containing involved tissue from tumor resection, core needle biopsy, or fine needle aspirate (i.e., cell pellet). Multiple blocks from a single case are acceptable. Include H&E stained slide for each block if available.

  2. Ten (10) unstained slides from an FFPE block containing involved tissue, with tissue sections of thickness 5-10 µm and one (1) H&E stained slide.

  3. Optimal tumor nuclei >70%, minimal >20%

  4. Peripheral blood in a lavender top EDTA collection tube, 5 mL or greater.  

For hematopoietic malignancies/disorders, the following specimen types are acceptable:

  1. Involved peripheral blood in a lavender top EDTA collection tube, 5 mL or greater

  2. Involved cellular bone marrow aspirate in a lavender top EDTA collection tube, 1 mL or greater

  3. Formalin fixed, paraffin embedded (FFPE) block(s) containing disease involved bone core (NOT acid decalcified) from bone marrow harvest. Include H&E stained slide if available.

  4. Ten (10) unstained slides from an FFPE block containing disease involved bone core (NOT acid decalcified) from bone marrow harvest, with tissue sections of thickness 5-10 µm, including H&E stained slide if available.

oncoped Get Started

Get Started

Ready to get started? Contact PierianDx today!

 CONTACT US Brochure